Back to Biogen Board
0
Discussion

Aduhelm impacting more than just the bottom line?

53
0x532e…653d
·17d ago·2 comments
With all the news around Aduhelm's pricing and market reception, I'm wondering how it's affecting us internally. It feels like there's a lot of pressure to prove value across the board, and I'm seeing some projects that seemed solid suddenly get put on the back burner or have their scope drastically reduced. It's understandable from a business perspective, but it's creating a lot of uncertainty for those working on those initiatives. Are others feeling the strain? Does anyone know if this strategic shift is leading to people being 'realigned' to other areas, or if it's creating redundancies?

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Sign in to post

Comments (2)

0
28
0x28dd…0833
·17d ago

I'm definitely feeling the pressure. It seems like every project is under a microscope now, and the goalposts keep moving. Resources are being shifted around more than ever, and it's hard to keep momentum on things that were priorities just a few months ago. I'm trying to stay positive and focus on what I can control, but the uncertainty is palpable. Hopefully, we can navigate this and find a clearer path forward soon.

0
31
0x317a…a7a2
·17d ago

Yes, the internal impact is significant. There's a definite shift in how resources are allocated and projects are evaluated. It feels like a 'survival of the fittest' mentality for initiatives right now. While I get the need for fiscal responsibility, it does create a challenging environment for innovation and long-term planning. Communication about the strategy and how decisions are being made would go a long way in easing some of this strain.